Both in Pharmaceuticals
Spyre Therapeutics vs Cytokinetics
Over the past year SYRE returned +317.7% and CYTK returned +4.7%; their daily moves had a correlation of 0.33.
SYRE +317.7% CYTK +4.7%Growth of $1, one year, split-adjusted
| Metric | SYRE | CYTK |
|---|---|---|
| Price | $99.33 | $62.86 |
| Market cap | $9.28B | $8.74B |
| Today | +4.00% | +1.34% |
| 1 month | +7.1% | +0.3% |
| 6 months | +39.9% | −18.5% |
| Year to date | +203.2% | −1.1% |
| 1 year | +306.1% | −1.1% |
| Revenue growth (YoY) | — | −57.1% |
| Gross margin | — | 90.5% |
| Net margin | — | −694.4% |
| P/E (TTM) | — | — |
| Price / sales | — | 129.1× |
| Net cash | $1.15B | $18.6M |
| Dividend yield | — | — |
| Volatility (60d) | 59.2% | 31.8% |
| Short % of float | 15.6% | 15.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).